fluticasone furoate/vilanterol vs Vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline

fluticasone furoate/vilanterol · Breo Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT01086384 · Phase 3 · completed

This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.

Reported efficacy

Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 (met)

Result source: NCT01086384

Vilanterol

Developed by GlaxoSmithKline

Phase 3 in Asthmasmall molecule
Partial signal

NCT00381667 · Phase 2 · completed

The study was randomized, double-blind, and placebo-controlled, but enrolled only 14 participants. Its primary outcomes included lung-function and safety measurements rather than a hard clinical endpoint, and the primary comparison cannot be assessed because results have not been posted.

Reported efficacy

Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) (mixed)

Result source: NCT00600171

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​vilanterolVilanterol
Severe exacerbations, annualised rate—Trial running · NCT05757102—Not reported
Trough FEV1, change0.4 vs 0.2+0.2 vs placebo100/25 µg OD · wk 12 · n 200NCT01165138
8 other results
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • 0.3 vs 0.3 100/25 µg OD · wk 24 · n 397 · Phase 3 · secondary NCT01147848
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 wk 12 · n 417 · Phase 3 · secondary NCT03248128
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.3 vs 0.2 wk 12 · n 307 · Phase 3 · secondary NCT03248128
0.3 vs 0.1+0.1 vs placebo25 µg · wk 4 · n 99NCT00600171
8 other results
  • 0.3 vs 0.1 50 µg · wk 4 · n 100 · Phase 2 · primary NCT00600171
  • 0.3 vs 0.1 12.5 µg · wk 4 · n 97 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 6.25 µg · wk 4 · n 99 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 3 µg · wk 4 · n 98 · Phase 2 · primary NCT00600171
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767
ACQ-5, change-1.2 vs -1.1vs FFwk 24 · n 385NCT03248128
1 other result
  • -1.3 vs -1.1 wk 24 · n 291 · Phase 3 · secondary NCT03248128
—Not reported
OCS dose reduction—Trial running · NCT05757102—Not reported

Severe exacerbations, annualised rate

fluticasone furoate/​vilanterol
—Trial running · NCT05757102
Vilanterol
—Not reported

Trough FEV1, change

fluticasone furoate/​vilanterol
0.4 vs 0.2+0.2 vs placebo100/25 µg OD · wk 12 · n 200NCT01165138
8 other results
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • 0.3 vs 0.3 100/25 µg OD · wk 24 · n 397 · Phase 3 · secondary NCT01147848
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 wk 12 · n 417 · Phase 3 · secondary NCT03248128
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.3 vs 0.2 wk 12 · n 307 · Phase 3 · secondary NCT03248128
Vilanterol
0.3 vs 0.1+0.1 vs placebo25 µg · wk 4 · n 99NCT00600171
8 other results
  • 0.3 vs 0.1 50 µg · wk 4 · n 100 · Phase 2 · primary NCT00600171
  • 0.3 vs 0.1 12.5 µg · wk 4 · n 97 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 6.25 µg · wk 4 · n 99 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 3 µg · wk 4 · n 98 · Phase 2 · primary NCT00600171
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767

ACQ-5, change

fluticasone furoate/​vilanterol
-1.2 vs -1.1vs FFwk 24 · n 385NCT03248128
1 other result
  • -1.3 vs -1.1 wk 24 · n 291 · Phase 3 · secondary NCT03248128
Vilanterol
—Not reported

OCS dose reduction

fluticasone furoate/​vilanterol
—Trial running · NCT05757102
Vilanterol
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. fluticasone furoate/vilanterol: 14 of 14 rows · Vilanterol: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​vilanterol
Rows use multiple source trials
Vilanterol
Rows use multiple source trials
Evening PEF
absolute change · L/min
26.4 vs -1.8 placebo L/min @ 12wk100/25 µg ODa,b,c,d
NCT01165138 · Phase 3
2 other source trials
39.7 vs 15.5 FF L/min @ 12wk100/25 µg OD
NCT01686633 · Phase 3
41.7 vs 15.5 FF L/min @ 12wk200/25 µg OD
NCT01686633 · Phase 3
34 vs 0.4 placebo L/min25 µge,a,b,c,d
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more doses
38.4 vs 0.4 placebo L/min50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
28.9 vs 0.4 placebo L/min12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
24.5 vs 0.4 placebo L/min6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
14 vs 0.4 placebo L/min3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Evening PEF Change L/Min
absolute change · L/min
5.5 vs 0.5 FP/S L/min @ 24wk100/25 mcg Once Dailya,b,c,f
NCT02301975 · Phase 3 · registry result, not featured evidence
220.3 vs 215.9 placebo L/min @ 4wk25 µg ODe,a,b,c,f
NCT01573767 · Phase 2 · registry result, not featured evidence
show 5 more doses
11.1 vs 5.9 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
222.4 vs 215.9 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.7 vs 5.9 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
221.4 vs 215.9 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
9.4 vs 5.9 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
FEV1
absolute change · L
0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailye,a,b,c,g
NCT02301975 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
-0.227 vs -0.372 placebo L @ 4.14wk100/25 µg ODa,b,c,g
NCT01128569 · Phase 2 · registry result, not featured evidence
FEV1 AUC0-24
absolute change · L
0.341 vs 0.377 Fluticasone Propionate/Salmeterol L @ 24wk100/25 µg ODa,h,c,f
NCT01147848 · Phase 3 · Asthma · phase 3
0.315 vs 0.149 placebo L @ 4wk25 µge,a,h,c,f
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more doses
0.321 vs 0.149 placebo L @ 4wk50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.292 vs 0.149 placebo L @ 4wk12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.253 vs 0.149 placebo L @ 4wk6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.3 vs 0.149 placebo L @ 4wk3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
FEV1 Wm0 24 h
absolute change · L
0.513 vs 0.212 placebo L @ 12wk100/25 µg ODb,c
NCT01165138 · Phase 3
2 other source trials
0.474 vs 0.366 FF L @ 12wk100/25 µg OD
NCT01686633 · Phase 3
0.499 vs 0.366 FF L @ 12wk200/25 µg OD
NCT01686633 · Phase 3
0.359 vs 0.289 placebo L @ 12wk25 µg ODb,c
NCT01181895 · Phase 3 · registry result, not featured evidence
Morning PEF
absolute change · L/min
14.9 vs 9.3 FF L/min @ 12wke,a,i,c,d
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more dose
11.9 vs 8.9 FF L/min @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
38.1 vs 1.9 placebo L/min25 µge,a,i,c,d
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more doses
44 vs 1.9 placebo L/min50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
34.2 vs 1.9 placebo L/min12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
26.8 vs 1.9 placebo L/min6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
18.7 vs 1.9 placebo L/min3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Rescue-free 24 h Periods
absolute change · percentage points
-0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b,c,d
NCT02094937 · Phase 3 · registry result, not featured evidence
43.4% (n=101) vs 15% (n=99) placebo25 µge,a,b,c,d
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more doses
34% (n=102) vs 15% (n=99) placebo50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
29.6% (n=98) vs 15% (n=99) placebo12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
27.3% (n=101) vs 15% (n=99) placebo6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
25.8% (n=99) vs 15% (n=99) placebo3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Rescue-free 24-h Period
percent change · % of baseline
37.1% (n=201) vs 17.8% (n=202) placebo @ 12wk100/25 µg ODb,c
NCT01165138 · Phase 3
3 other source trials
34.8% (n=345) vs 22.6% (n=346) FF @ 12wk100/25 µg OD
NCT01686633 · Phase 3
35.8% (n=346) vs 22.6% (n=346) FF @ 12wk200/25 µg OD
NCT01686633 · Phase 3
30.1% (n=153) vs 8.3% (n=154) placebo @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
21.7% (n=115) vs 14.6% (n=115) placebo @ 12wk25 µg ODb,c
NCT01181895 · Phase 3 · registry result, not featured evidence
Symptom-free 24 h Periods
absolute change · percentage points
-3.5% (n=500) vs -4.7% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b,c,d
NCT02301975 · Phase 3 · registry result, not featured evidence
36.4% (n=101) vs 14.2% (n=98) placebo25 µge,a,b,c,d
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more doses
32.3% (n=102) vs 14.2% (n=98) placebo50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
26.8% (n=98) vs 14.2% (n=98) placebo12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
23.6% (n=101) vs 14.2% (n=98) placebo6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
22.6% (n=99) vs 14.2% (n=98) placebo3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Symptom-free 24-h Period
percent change · % of baseline
32.5% (n=201) vs 14.6% (n=202) placebo @ 12wk100/25 µg ODb,c
NCT01165138 · Phase 3
3 other source trials
27.2% (n=345) vs 19.4% (n=346) FF @ 12wk100/25 µg OD
NCT01686633 · Phase 3
29% (n=346) vs 19.4% (n=346) FF @ 12wk200/25 µg OD
NCT01686633 · Phase 3
24.8% (n=153) vs 9% (n=154) placebo @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
19.4% (n=115) vs 12.7% (n=115) placebo @ 12wk25 µg ODb,c
NCT01181895 · Phase 3 · registry result, not featured evidence
Dropout rate
—100/25 µgj
NCT01086384 · Phase 3
show 16 more results
—200/25 µg OD
NCT01018186 · Phase 3
—100/25 µg OD
NCT01018186 · Phase 3
—
NCT03248128 · Phase 3 · Asthma · phase 3
10.9%100/25 µg OD
NCT01165138 · Phase 3
7.2%200/25 µg OD
NCT01686633 · Phase 3
9.2%100/25 µg OD
NCT01686633 · Phase 3
14.2%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
—100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
—100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
6.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
14.4%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
12.3%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
7.9%25 µgk
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
4.9%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
9.9%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
16.8%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12.2%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
21.1%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12.4%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
18.4%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—100/25 µgj
NCT01086384 · Phase 3
show 16 more results
—200/25 µg OD
NCT01018186 · Phase 3
—100/25 µg OD
NCT01018186 · Phase 3
—
NCT03248128 · Phase 3 · Asthma · phase 3
1%100/25 µg OD
NCT01165138 · Phase 3
0.9%200/25 µg OD
NCT01686633 · Phase 3
0.9%100/25 µg OD
NCT01686633 · Phase 3
3.6%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
—100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
—100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
1.6%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
2.6%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
1.3%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
1%25 µgk
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
0%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
1%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.9%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
0.9%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Serious AEs
4.1%100/25 µgj
NCT01086384 · Phase 3
show 16 more results
0.5%200/25 µg OD
NCT01018186 · Phase 3
1.5%100/25 µg OD
NCT01018186 · Phase 3
1.1%
NCT03248128 · Phase 3 · Asthma · phase 3
0%100/25 µg OD
NCT01165138 · Phase 3
0.3%200/25 µg OD
NCT01686633 · Phase 3
1.2%100/25 µg OD
NCT01686633 · Phase 3
3%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
1%100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
1.4%100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
1.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.8%100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0%100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
1.3%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
0.6%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0%100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
0%25 µgk
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
0%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.9%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
—25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
0%100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
0%25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100/25 µgj
headache 18.6%
nasopharyngitis 15.4%
upper respiratory tract infection 7.2%
NCT01086384 · Phase 3
show 15 more results
200/25 µg OD
headache 17.3%
upper respiratory tract infection 14.9%
nasopharyngitis 9.4%
NCT01018186 · Phase 3
100/25 µg OD
headache 19.4%
upper respiratory tract infection 16.9%
nasopharyngitis 12.4%
NCT01018186 · Phase 3
nasopharyngitis 10.4%
upper respiratory tract infection 7%
rhinitis allergic 4.2%
NCT03248128 · Phase 3 · Asthma · phase 3
100/25 µg OD
nasopharyngitis 10% (placebo 7.4%)
headache 5% (placebo 3.9%)
NCT01165138 · Phase 3
200/25 µg OD
headache 8.4%
nasopharyngitis 7.2%
upper respiratory tract infection 2%
NCT01686633 · Phase 3
100/25 µg OD
headache 8.4%
nasopharyngitis 6.4%
upper respiratory tract infection 2.3%
NCT01686633 · Phase 3
200/25 µg OD
nasopharyngitis 12.7%
headache 5.6%
bronchitis 3.6%
NCT01134042 · Phase 3 · combination · Asthma · phase 3
100/25 µg OD
nasopharyngitis 11.4%
headache 8.4%
upper respiratory tract infection 6.2%
NCT01147848 · Phase 3 · Asthma · phase 3
100/25 µg QD
upper respiratory tract infection 6.8%
NCT02730351 · Phase 4 · registry result, not featured evidence
100/25 mcg Once Daily
nasopharyngitis 12.1%
headache 8.1%
bronchitis 4%
NCT02301975 · Phase 3 · registry result, not featured evidence
100 mcg once daily
nasopharyngitis 17.9%
NCT02094937 · Phase 3 · registry result, not featured evidence
100/25 mcg once daily
nasopharyngitis 15.6%
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
100/25 µg Once Daily
upper respiratory tract infection 7.2% (placebo 9.1%)
headache 4.6% (placebo 1.9%)
nasopharyngitis 4.6% (placebo 8.4%)
NCT01498679 · Phase 3 · registry result, not featured evidence
200/25 µg Once Daily
upper respiratory tract infection 8.4%
nasopharyngitis 3.9%
rhinitis allergic 3.2%
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
100 µg/25 µg
bronchitis 4%
conjunctivitis 4%
headache 4%
NCT01453023 · Phase 2 · registry result, not featured evidence
25 µgk
headache 6.9% (placebo 7.8%)
upper respiratory tract infection 2% (placebo 2%)
nasopharyngitis 0% (placebo 3.9%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 13 more results
50 µg
headache 7.8% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 2% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12.5 µg
headache 9% (placebo 7.8%)
upper respiratory tract infection 3% (placebo 2%)
nasopharyngitis 0% (placebo 3.9%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
6.25 µg
headache 6.9% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 1% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
3 µg
headache 11.9% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 2% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
25 µg OD
headache 8.7% (placebo 4.3%)
nasopharyngitis 7.8% (placebo 10.3%)
oropharyngeal pain 5.2% (placebo 6%)
NCT01181895 · Phase 3 · registry result, not featured evidence
12.5 OD
nasopharyngitis 8.8% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
25 OD
nasopharyngitis 7.9% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
6.25 OD
nasopharyngitis 7% (placebo 7%)
headache 5.3% (placebo 3.5%)
influenza 3.5% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
100/25 µg AM
headache 25% (placebo 26.1%)
nasopharyngitis 12.5% (placebo 13%)
dysmenorrhoea 4.2% (placebo 0%)
NCT01287065 · Phase 2 · registry result, not featured evidence
100/25 µg PM
headache 32% (placebo 26.1%)
gastroenteritis 8% (placebo 0%)
nasopharyngitis 8% (placebo 13%)
NCT01287065 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 55.6% (placebo 40.7%)
nasopharyngitis 11.1% (placebo 7.4%)
oropharyngeal pain 11.1% (placebo 7.4%)
NCT01128595 · Phase 2 · registry result, not featured evidence
25 µg
upper respiratory tract infection 11.1% (placebo 0%)
headache 7.4% (placebo 7.7%)
pyrexia 7.4% (placebo 0%)
NCT01453296 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 9.8% (placebo 17.6%)
dysphonia 3.9% (placebo 0%)
mouth ulceration 3.9% (placebo 0%)
NCT01128569 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fAssessment timepoints differ: 4 weeks versus 24 weeks.
  7. gAssessment timepoints differ: 4.14 weeks versus 24 weeks.
  8. hPopulation context differs: baseline_threshold differs (fev1_pct_predicted>=40 versus fev1_pct_predicted<=85, fev1_pct_predicted>=40); prior_therapy differs (experienced versus none recorded).
  9. iPopulation context differs: age eligibility differs (adolescents and adults versus includes children); baseline_threshold differs (fev1_pct_predicted>=40 versus fev1_pct_predicted<=90, fev1_pct_predicted>50).
  10. jPopulation comparability has not been reviewed for 13 of these studies.
  11. kPopulation comparability has not been reviewed for 12 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/vilanterol

Severe Exacerbation Occurrence 15.3% (n=1009) vs 18.4% (n=1010) fluticasone furoate @ 76wk100/25 µg
event count · % of participants
NCT01086384 · Phase 3 · converted to % from 154 participants as posted
Severe Exacerbation Rate Annualized 200 vs 271 fluticasone furoate Severe asthma exacerbations @ 76wk100/25 µg
event rate · Severe asthma exacerbations
NCT01086384 · Phase 3
FEV1 Weighted Mean 0-4h 2.082 vs 1.994 FF L @ 12wk
absolute value · L
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
1.762 vs 1.711 FF L @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Rescue-free 24-h Period 25.9% (n=453) vs 25.8% (n=447) FF @ 12wk
absolute change · percentage points
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
27.3% (n=336) vs 25.6% (n=335) FF @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Symptom-free 24-h Period 25.7% (n=453) vs 24.6% (n=447) FF @ 12wk
absolute change · percentage points
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
27.2% (n=336) vs 25.8% (n=335) FF @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
ACQ-5 -1.21 vs -1.09 FF score @ 24wk
absolute change · score
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
-1.25 vs -1.13 FF score @ 24wk
NCT03248128 · Phase 3 · Asthma · phase 3
AQLQ Total 0.8 vs 0.69 Fluticasone Propionate score @ 12wk200/25 µg Once Daily
absolute change · score
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
show 4 more results
0.91 vs 0.61 placebo score @ 12wk100/25 µg OD
NCT01165138 · Phase 3
0.84 vs 0.33 placebo score @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
0.74 vs 0.66 FF score @ 12wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.93 vs 0.88 FF score @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
FEV1 Trough 2.83 vs 2.462 placebo L @ 12wk100/25 µg OD
absolute value · L
NCT01165138 · Phase 3
ACT Total 4.4 vs 2.5 placebo score @ 12wk100/25 µg OD
absolute change · score
NCT01165138 · Phase 3
show 1 more result
-0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
Rescue-free 24-h Period 38.2% (n=197) vs 26.6% (n=193) FF @ 24wk200/25 µg OD
absolute change · percentage points
Rescue-free 24-hour periods
NCT01134042 · Phase 3 · combination · Asthma · phase 3
Symptom-free 24-h Period 29.3% (n=197) vs 21% (n=193) FF @ 24wk200/25 µg OD
absolute change · percentage points
Symptom-free 24-hour periods
NCT01134042 · Phase 3 · combination · Asthma · phase 3
FEV1 AUC0-4 0.316 vs 0.346 Fluticasone Propionate/Salmeterol L @ 0wk100/25 µg OD
absolute change · L
NCT01147848 · Phase 3 · Asthma · phase 3
show 1 more result
0.36 vs 0.394 Fluticasone Propionate/Salmeterol L @ 24wk100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3

+ 8 further endpoints in the CSV export.

Vilanterol

FEV1 0.33 vs 0.301 placebo L @ 12wk25 µg OD
absolute change · L
24 hours, n= 95, 101, 100
NCT01181895 · Phase 3 · registry result, not featured evidence
Morning PEF Change L/Min 13.7 vs 6.4 placebo L/min @ 4wk25 µg OD
absolute change · L/min
NCT01573767 · Phase 2 · registry result, not featured evidence
show 5 more results
14.4 vs 7.4 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.9 vs 6.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
17 vs 7.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12 vs 6.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.3 vs 7.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
FEV1 Trough 3.191 vs 2.788 placebo L @ 2wk100/25 µg AM
absolute change · L
AM, n=22, 24, 25
NCT01287065 · Phase 2 · registry result, not featured evidence
show 1 more result
3.285 vs 2.788 placebo L @ 2wk100/25 µg PM
AM, n=22, 24, 25
NCT01287065 · Phase 2 · registry result, not featured evidence
FEV1 Evening Trough 3.153 vs 2.879 placebo L @ 2wk100/25 µg AM
absolute change · L
PM, n=23, 24, 25
NCT01287065 · Phase 2 · registry result, not featured evidence
show 1 more result
3.188 vs 2.879 placebo L @ 2wk100/25 µg PM
PM, n=23, 24, 25
NCT01287065 · Phase 2 · registry result, not featured evidence
LAR Min FEV1 Change -0.216 vs -0.731 placebo L @ 3wk100/25 µg OD
absolute change · L
NCT01128595 · Phase 2 · registry result, not featured evidence
FEV1 Max Change Pct 0-2h -10.43% (n=27) vs -26.13% (n=22) placebo @ 3wk100/25 µg OD
percent change · % of baseline
NCT01128595 · Phase 2 · registry result, not featured evidence
show 1 more result
-13.206% (n=46) vs -24.991% (n=45) placebo @ 4.14wk100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
PC20 2.5 vs 1.046 placebo mg @ 3.14wk100/25 µg OD
absolute value · mg
NCT01128595 · Phase 2 · registry result, not featured evidence
LAR WM FEV1 Change 0.018 vs -0.466 placebo L @ 3wk100/25 µg OD
absolute change · L
NCT01128595 · Phase 2 · registry result, not featured evidence
EAR Min FEV1 Change -0.614 vs -1.091 placebo L @ 3wk100/25 µg OD
absolute change · L
NCT01128595 · Phase 2 · registry result, not featured evidence
EAR WM FEV1 Change -0.297 vs -0.56 placebo L @ 3wk100/25 µg OD
absolute change · L
NCT01128595 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · Vilanterol's landscape